Resources

Selected
  • RSV
  • RSV (Respiratory syncytial virus)
Type of publications
Regions
Diseases
Methodological quality (AMSTAR 2)

71 results found

2025 ∙ Health Council of the Netherlands

RSV vaccination for the elderly

  • Recommendation
  • Europe
  • Netherlands
  • RSV (Respiratory syncytial virus)
2024 ∙ Zeng, B. Liu, X. Yang, Q. Wang, J. Ren, Q. Sun, F.

Efficacy and safety of vaccines to prevent respiratory syncytial virus infection in infants and older adults: A systematic review and meta-analysis

  • Adults
  • Older adults
  • Pregnant women
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Moreira, A. C. Ribeiro, A. B. Oliveira, I. Sa, M. Lameirao, C. Marques, P.

Efficacy of anti-RSV vaccination in preventing respiratory syncytial virus disease and severe illness in older adults: a systematic review of randomized controlled trials

  • Adults
  • Older adults
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2024 ∙ Ricco, M. Cascio, A. Corrado, S. Bottazzoli, M. Marchesi, F. Gili, R. Giuri, P. G. Gori, D. Manzoni, P.

Efficacy of Respiratory Syncytial Virus Vaccination to Prevent Lower Respiratory Tract Illness in Older Adults: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  • Adults
  • Older adults
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Low
2024 ∙ Pang, Y. Lu, H. Cao, D. Zhu, X. Long, Q. Tian, F. Long, X. Li, Y.

Efficacy, immunogenicity and safety of respiratory syncytial virus prefusion F vaccine: systematic review and meta-analysis

  • Adults
  • Older adults
  • Pregnant women
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Wu, Y. Bai, Y. Zhu, B. Chang, F. Lu, Y.

Efficacy, Safety, and Immunogenicity of Subunit Respiratory Syncytial Virus Vaccines: Systematic Review and Meta-Analysis of Randomized Controlled Trials

  • Pregnant women
  • Adults
  • Older adults
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Moderate
2024 ∙ Mapindra, M. P. Mahindra, M. P. McNamara, P. Semple, M. G. Clark, H. Madsen, J.

Respiratory Syncytial Virus Maternal Vaccination in Infants below 6 Months of Age: Meta-Analysis of Safety, Immunogenicity, and Efficacy

  • Pregnant women
  • Newborn
  • RSV (Respiratory syncytial virus)
  • Safety
  • Efficacy/effectiveness
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ Phijffer, Ewem de Bruin, O. Ahmadizar, F. Bont, L. J. Van der Maas, N. A. T. Sturkenboom, Mcjm Wildenbeest, J. G. Bloemenkamp, K. W. M.

Respiratory syncytial virus vaccination during pregnancy for improving infant outcomes

  • Pregnant women
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
High
2024 ∙ Wroblewski, D. Brust-Sisti, L. A. Bridgeman, M. Bridgeman, M. B.

Vaccines for Respiratory Syncytial Virus Prevention in Older Adults

  • Adults
  • Older adults
  • RSV (Respiratory syncytial virus)
  • Efficacy/effectiveness
  • Safety
Methodological quality (AMSTAR 2):
Critically low
2024 ∙ SAGE

Meeting of the Strategic Advisory Group of Experts on Immunization, March 2024: conclusions and recommendations

  • Meeting report
  • Poliomyelitis
  • Hepatitis E
  • COVID-19
  • Mpox
  • RSV (Respiratory syncytial virus)
Loading...